Study for the clearing and treat familial neurological relentless disease by using disease patient induced pluripotent stem cells.

Study for the clearing and treat familial neurological relentless disease by using disease patient induced pluripotent stem cells. - Study for the clearing and treat familial neurological relentless disease by using disease patient iPSCs.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047097

Enrollment

Registered

2023-04-01

Start date

2021-09-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ALS, SCD, Alzheimer&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Having the gene mutation in ALS, SCD, Alzheimer's disease, Parkinson's disease, familial polyneuropathy, muscle dystrophy, or cerebrovascular disease.

Exclusion criteria

Exclusion criteria: Inappropriate patient judged by the cordinator.

Design outcomes

Primary

Measure	Time frame
Finding the effectiveness drug from the iPSC model and validating the effectiveness to the real patient.	—

Countries

Japan

Contacts

Public ContactKosuke Matsuzono

Jichi Medical University Division of Neurology, Department of Medicine

kmatsuzono51@jichi.ac.jp0285-58-7352

Outcome results